Image Guided Planning for Prostate Carcinomas With Incorporation of Anti-3-[18F]FACBC (Fluciclovine) Positron Emission Tomography: Workflow and Initial Findings From a Randomized Trial.
Image Guided Planning for Prostate Carcinomas With Incorporation of Anti-3-[18F]FACBC (Fluciclovine) Positron Emission Tomography: Workflow and Initial Findings From a Randomized Trial.
复制标题
DOI：
10.1016/j.ijrobp.2016.04.023
复制
发表时间：
2016-09-01
期刊：
影响因子：
--
通讯作者：
Jani AB
中科院分区：
文献类型：
--
作者：
Schreibmann E;Schuster DM;Rossi PJ;Shelton J;Cooper S;Jani AB
18 F-氟硝草素（抗1-氨基-3-[18 F]氟环丁烷-1-羧酸）是一种新型正电子发射断层扫描（PET）/计算机断层扫描（CT）放射性示踪剂，已被证明可用于检测前列腺癌。我们的目标是报告一项随机对照试验的初步结果，该试验将18F-氟草胺PET-CT整合到治疗计划中，以确定前列腺床和淋巴结靶体积。我们报告了41例患者的初步研究结果，这些患者是随机对照试验的第一批患者，随机分配到18 F-氟草苷组，所有患者均接受了18 F-氟草苷PET-CT检查代谢异常和高分辨率CT治疗计划。首先使用刚性配准对2个数据集进行配准。如果可观察到软组织位移，则使用可变形配准来改善刚性配准。每个18F-氟草苷异常被分割为病变周围感兴趣的小区域内的最大标准摄取值（SUV）的百分比。通过扩大PET异常的标准靶体积，将最佳描述SUV下降的百分比整合到计划中。在55例异常中的21例中，需要进行变形配准以将18F-氟草胺活性映射到模拟CT中。最多选择的百分比是最大SUV的50%，尽管特定患者使用的值范围为15%至70%，说明需要按患者选择阈值SUV值。纳入18F-氟草苷改变了总共55例异常中46例（83%）的计划体积，其中28例（51%）位于淋巴结，11例（20%）位于前列腺床，10例（18%）位于前列腺，6例（11%）位于精囊。基于CT分割，仅9例PET异常完全包含在标准靶体积中，无需扩展。18F-氟氯烟酸在前列腺切除术后放射治疗计划中的使用是可行的，并导致大多数（41例中的30例）患者的靶体积增加。
18F-Fluciclovine (anti-1-amino-3-[18F]fluorocyclobutane-1-carboxylic acid) is a novel positron emission tomography (PET)/computed tomography (CT) radio-tracer that has demonstrated utility for detection of prostate cancer. Our goal is to report the initial results from a randomized controlled trial of the integration of 18F-fluciclovine PET-CT into treatment planning for defining prostate bed and lymph node target volumes. We report our initial findings from a cohort of 41 patients, of the first enrolled on a randomized controlled trial, who were randomized to the 18F-fluciclovine arm. All patients underwent 18F-fluciclovine PET-CT for the detection of metabolic abnormalities and high-resolution CT for treatment planning. The 2 datasets were registered first by use of a rigid registration. If soft tissue displacement was observable, the rigid registration was improved with a deformable registration. Each 18F-fluciclovine abnormality was segmented as a percentage of the maximum standard uptake value (SUV) within a small region of interest around the lesion. The percentage best describing the SUV falloff was integrated in planning by expanding standard target volumes with the PET abnormality. In 21 of 55 abnormalities, a deformable registration was needed to map the 18F-fluciclovine activity into the simulation CT. The most selected percentage was 50% of maximum SUV, although values ranging from 15% to 70% were used for specific patients, illustrating the need for a per-patient selection of a threshold SUV value. The inclusion of 18F-fluciclovine changed the planning volumes for 46 abnormalities (83%) of the total 55, with 28 (51%) located in the lymph nodes, 11 (20%) in the prostate bed, 10 (18%) in the prostate, and 6 (11%) in the seminal vesicles. Only 9 PET abnormalities were fully contained in the standard target volumes based on the CT-based segmentations and did not necessitate expansion. The use of 18F-fluciclovine in postprostatectomy radiation therapy planning was feasible and led to augmentation of the target volumes in the majority (30 of 41) of the patients studied.
登录
查看更多内容
影响因子：
6.7
作者：
Eiber, Matthias;Beer, Ambros J.;Gaa, Jochen
通讯作者：
Gaa, Jochen
影响因子：
3.1
作者：
Okudaira H;Oka S;Ono M;Nakanishi T;Schuster DM;Kobayashi M;Goodman MM;Tamai I;Kawai K;Shirakami Y
通讯作者：
Shirakami Y
影响因子：
1.6
作者：
McConathy, J;Voll, RJ;Goodman, MM
通讯作者：
Goodman, MM
DOI：
10.1016/j.ijrobp.2008.08.002
发表时间：
2009-06-01
影响因子：
7
作者：
Lawton, Colleen A. F.;Michalski, Jeff;Seider, Michael
通讯作者：
Seider, Michael
影响因子：
3.5
作者：
Hong, Hao;Zhang, Yin;Sun, Jiangtao;Cai, Weibo
通讯作者：
Cai, Weibo